Skip to main navigation Skip to search Skip to main content

Identification of novel inhibitors of UDP-Glc 4 '-epimerase, a validated drug target for African sleeping sickness

  • Michael D. Urbaniak
  • , Jioji N. Tabudravu
  • , Aichi Msaki
  • , Kathy Mansfield Matera
  • , Ruth Brenk
  • , Marcel Jaspars
  • , Michael A. J. Ferguson

    Research output: Contribution to journalArticlepeer-review

    Abstract

    Novel inhibitors of Trypanosoma brucei and mammalian UDP-Glc 4'-epimerase were identified by screening a small library of natural products and commercially available drug-like molecules. The inhibitors possess low micromolar potency against the T brucei and human enzymes in vitro, display a degree of selectivity between the two enzymes, and are cytotoxic to cultured T. brucei and mammalian cells. (c) 2006 Elsevier Ltd. All rights reserved.

    Original languageEnglish
    Pages (from-to)5744-5747
    Number of pages4
    JournalBioorganic & Medicinal Chemistry Letters
    Volume16
    Issue number22
    DOIs
    Publication statusPublished - 15 Nov 2006

    UN SDGs

    This output contributes to the following UN Sustainable Development Goals (SDGs)

    1. SDG 3 - Good Health and Well-being
      SDG 3 Good Health and Well-being

    Fingerprint

    Dive into the research topics of 'Identification of novel inhibitors of UDP-Glc 4 '-epimerase, a validated drug target for African sleeping sickness'. Together they form a unique fingerprint.

    Cite this